对比剂肾病的防治进展

Abstract
Figure/Table
References (32)
Related Citation (15)

Download: PDF (765 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Contrast-induced nephropathy (CIN) is a common reversible acute renal failure in clinical practice. The incidence rate of CIN is increasing annually with the widely use of contrast agents such as angiography, coronary angiography, cerebral angiography, or other medical related radiography (urography and cholangiography). It has been an important cause of acute kidney injury after ischemia and drug injury. Nowadays, the mechanism of CIN induced by contrast agent is not completely clear, mainly including oxidative stress and apoptosis. In addition, many studies have also found that renal ischemia and tubular toxic injury are also the key pathological mechanisms of CIN. The occurrence of CIN is not only related to the increased medical expenses, but also leads to a significant increase in the risk of adverse outcomes (such as acute myocardial infarction, acute heart failure, dialysis and death). Therefore, early identification of risk factors for CIN and appropriate clinical intervention will help high-risk CIN patients benefit from early renal protection strategies and improve prognosis. This study reviews the diagnosis of CIN and the progress of current treatment measures, so as to provide basis for clinical practice.

Key words： Contrast agent Contrast-induced nephropathy Renal insufficiency Prevention and treatment

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors

Cite this article:

URL:

https://www.dangdaiyiyao.com/EN/ OR https://www.dangdaiyiyao.com/EN/Y2022/V29/I8/33

[1]	段鹏，张小勇，张赛丹.大剂量阿托伐他汀序贯治疗对急性非ST 段抬高型心肌梗死患者围手术期对比剂肾病的影响[J].中国动脉硬化杂志，2016，24（7）：711-714.
[2]	Ozkok SA.Contrast-induced acute kidney injury：A review of practical points[J].World J Nephrol，2017（3）：86-99.
[3]	陈军，焦占全，李广平.MPO、NO 在造影剂肾病中的表达及其与氧化应激的关系[J].中外医学研究，2012（6）：1-3.
[4]	王立利，刘冲.不同PCI 术对急性心梗患者心功能和心率变异性影响[J].现代仪器与医疗，2016，22（2）：68-70.
[5]	Pucelikova T，Dangas G，Mehran R.Contrast-induced nephropathy[J].Catheter Cardio Inte，2008，71（1）：62-72.
[6]	Lian D，Liu Y，Liu YH，et al.Pre-procedural risk score of contrast-induced nephropathy in elderly patients undergoing elective coronary angiography[J].Int Heart J，2017，58（2）：197-204.
[7]	Wang YY，Li T，Liu YW，et al.Ischemic postconditioning before percutaneous coronary intervention for acute ST-segment elevation myocardial infarction reduces contrast-induced nephropathy and improves long-term prognosis[J].Arch Med Res，2016，47（6）：483-488.
[8]	Pakfetrat M，Nikou M，Malek L，et al.Risk Factors for contrast-related acute kidney injury according to risk，injury，failure，loss，and end-stage criteria in patients with coronary interventions[J].IJKD，2010，4（2）：116-122.
[9]	陈友权，蔡万强，余盛龙，等.阿托伐他汀与水化疗法联用预防PCI 术后对比剂肾病的研究[J].临床医学工程，2014（8）：970-972.
[10]	Komiyama K，Ashikaga T，Inagaki D，et al.Sodium bicarbonate-ascorbic acid combination for prevention of contrast-induced nephropathy in chronic kidney disease patients undergoing catheterization[J].Circ J，2017，81（2）：235-240.
[11]	纪芳杰，丛洪良，杨世诚，等.强化阿托伐他汀治疗对高血压合并慢性肾功能不全患者经皮冠状动脉介入治疗后对比剂肾病的预防作用[J].中华高血压杂志，2013，21（6）：577-581.
[12]	Banda J，Duarte R，Dickens C，et al.Risk factors and outcomes of c ontrast-induced nephropathy in hospitalised South Africans[J].S Afr Med J，2016，106（7）：699-703.
[13]	Kumar S，Nair RK，Aggarwal N，et al.Risk factors for contrast-induced nephropathy after coronary angiography[J].Saudi J Kidney Dis Transpl，2017，28（2）：318-324.
[14]	Patti G，Ricottini E，Nusca A，et al.Short-term，high-dose Atorvastatin pretreatment to prevent contrast -induced nephropathy in patients with acute coronary syndromes undergoing percutaneous coronary intervention from the ARMYDA-CIN [atorvastatin for reduction of myocardial damage during angioplasty——contrast-induced nephropathy] trial[J].Am J Cardiol，2011，108（1）：1-7.
[16]	许骥，华琦，郝恒剑，等.术前强化他汀治疗联合碘克沙醇对70 岁以上患者PCI 术后肾功能的保护作用[J].中国临床药理学与治疗学，2016，21（1）：82-86.
[20]	Iwaki F，Amano H，Ohura K.Nicorandil inhibits osteoclast differentiation in vitro[J].Eur J Pharmacol，2016，15（793）：14-20.
[15]	Liu LY，Liu Y，Wu MY，et al.Efficacy of atorvastatin on the prevention of contrast-induced acute kidney injury：a meta-analysis[J].Drug Des Devel Ther，2018，12：437-444.
[17]	Chana RS，Sidaway JE，Brunskill NJ.Statins but not thiazolidinediones attenuate albumin-mediated chemokine production by proximal tubular cells independently of endocytosis[J].Am J Nephrol，2008，28（5）：823-830.
[18]	Roy CU，Bahler CK，Holman BH，et al.ATP-sensitive potassium （KATP） channel openers diazoxide and nicorandil lower intraocular pressure by activating the Erk1/2 signaling pathway[J].PLoS One，2017，12（6）：e0179345.
[19]	Santillo E，Migale M，Postacchini D，et al.Cardioprotection by Conditioning Mimetic Drugs[J].Antiinflamm Antiallergy Agents Med Chem，2016，15（1）：15-30.
[21]	Menon R，Mohd Noor FS，Draman CR，et al.A retrospective review of diabetic nephropathy patients during referral to the sub-urban nephrology clinic[J].Saudi J Kidney Dis Transpl，2012，23（5）：1109-1114.
[22]	Wong PC，Li Z，Guo J，Zhang A.Pathophysiology of contrast-induced nephropathy[J].Int J Cardiol，2012，12（158）：186-92.
[23]	Miao Y，Zhong Y，Yan H，et al.Alprostadil plays a protective role in contrast-induced nephropathy in the elderly[J].Int Urol Nephrol，2013，45（4）：1179-1185.
[24]	Li WN，Feng Z.Effect of alprostadil on patients with acute kidney injury[J].Chin Trop Med，2012（11）：42.
[25]	王振璞，曲青山，苗书斋.前列地尔促进移植肾功能的早期恢复[J].中国组织工程研究，2013（44）：7687-7692.
[26]	曹磊，罗红.小剂量多巴胺联合前列地尔治疗慢性肾功能不全临床研究[J].淮海医药，2012，30（1）：31-33.
[27]	Wei XB，Jiang L，Liu XR，et al.Brain natriuretic peptide for prevention of contrast-induced nephropathy：a metaanalysis of randomized controlled trials[J].Eur J Clin Pharmacol，2016，72（11）：1311-1318.
[28]	吴小庆，孙铸兴，王强，等.重组脑钠肽静脉注射对失代偿心力衰竭患者肾功能、肾素活性和血醛固酮的影响[J].中国微循环，2009，13（4）：294-297.
[29]	Xing K，Fu X，Wang Y，et al.Effect of rhBNP on renal function in STEMI-HF patients with mild renal insufficiency undergoing primary PCI[J].Heart Vessels，2016，31（4）：490-8.
[30]	Zusman RM，Chesebro JH，Comerota A，et al.Antiplatelet therapy in the prevention of ischemic vascular events：literature review and evidence-based guidelines for drug selection[J].Clin Cardiol，1999，22（9）：559-573.
[31]	Lee BJ，Tseng YF，Yen CH，et al.Effects of coenzyme Q10 supplementation （300 mg/day） on antioxidation and antiinflammation in coronary artery disease patients during statins therapy：a randomized，placebo-controlled trial[J].Nutr J，2013，12（1）：142.
[32]	Guo H，Li MJ，Liu QQ，et al.Danhong injection attenuates ischemia/reperfusion-induced brain damage which is associating with Nrf2 levels in vivo and in vitro[J].Neurochem Res，2014，9（9）：1817-24.